Click here to receive MS news via e-mail
Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS
About MAVENCLAD(TM) (Cladribine Tablets) - Cladribine Tablets is a short-course oral therapy that is believed to selectively and periodically target lymphocytes thought to be integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States, Canada and Europe. In June 2017, the Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion on the use of Cladribine Tablets for highly active relapsing MS, and this recommendation has been passed on to the EC to make the final decision on the Marketing Authorization Application (MAA) later this year.
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis.